Cycurion, Inc. Announces Nasdaq Delisting Determination Letter
Cycurion (NASDAQ: CYCU) received a Delisting Determination Letter from Nasdaq staff dated October 14, 2025, initiating proceedings to delist its common stock for failing to meet the $1.00 bid price requirement. The company did not regain compliance by the October 6, 2025 deadline.
Cycurion requested an appeal on October 20, 2025, which stays suspension and the Form 25-NSE filing pending a Hearings Panel decision (hearings typically occur ~30–45 days after request). The board approved a 30:1 reverse stock split on October 10, 2025, expected to take effect on October 27, 2025. If delisted, shares may move to the over-the-counter market, which is likely to be less liquid.
Cycurion (NASDAQ: CYCU) ha ricevuto una Delisting Determination Letter da parte dello staff di Nasdaq datata 14 ottobre 2025, avviando le procedure per la cancellazione della sua azione ordinaria per non aver rispettato il requisito del prezzo di offerta di 1,00 dollari. L'azienda non è riuscita a tornare in conformità entro la scadenza del 6 ottobre 2025.
Cycurion ha richiesto un ricorso il 20 ottobre 2025, che sospende la sospensione e la presentazione del modulo Form 25-NSE in attesa di una decisione del Hearings Panel (le udienze di solito si svolgono circa 30–45 giorni dopo la richiesta). Il consiglio ha approvato un frazionamento azionario inverso 30:1 il 10 ottobre 2025, che dovrebbe entrare in vigore il 27 ottobre 2025. Se la quotazione viene cancellata, le azioni potrebbero passare al mercato over-the-counter, che tende ad essere meno liquido.
Cycurion (NASDAQ: CYCU) recibió una Delisting Determination Letter por parte del personal de Nasdaq con fecha 14 de octubre de 2025, iniciando procedimientos para eliminar su acción ordinaria por no cumplir con el requisito de precio de oferta de 1,00 USD. La empresa no recuperó el cumplimiento antes de la fecha límite del 6 de octubre de 2025.
Cycurion solicitó una apelación el 20 de octubre de 2025, lo que mantiene la suspensión y la presentación del Form 25-NSE en espera de una decisión del Panel de Audiencias (las audiencias suelen realizarse ~30–45 días después de la solicitud). La junta aprobó un dividendo inverso de 30:1 el 10 de octubre de 2025, con la entrada en vigor prevista para el 27 de octubre de 2025. Si se elimina la cotización, las acciones podrían pasar al mercado de over-the-counter, que probablemente será menos líquido.
Cycurion (NASDAQ: CYCU)은 2025년 10월 14일자로 Nasdaq 직원으로부터 상장폐지 결정 통보를 받았으며, $1.00의 매수가격 요건을 충족하지 못해 보통주를 상장폐지하는 절차를 시작했습니다. 회사는 2025년 10월 6일 마감일까지 적합성을 회복하지 못했습니다.
Cycurion은 2025년 10월 20일에 항소를 요청했고, 이는 중단 및 Form 25-NSE 제출을 보류하고 청문 패널의 결정까지 대기하는 상태로 남깁니다(청문은 보통 요청 후 약 30~45일 정도 소요됩니다). 이사회는 30:1의 역분할을 2025년 10월 10일에 승인했으며, 발효일은 2025년 10월 27일로 예상됩니다. 상장이 폐지되면 주식은 장외시장(over-the-counter)으로 이동할 수 있으며, 이는 유동성이 더 낮을 가능성이 큽니다.
Cycurion (NASDAQ: CYCU) a reçu une Lettre de détermination de radiation du personnel de Nasdaq datée le 14 octobre 2025, ouvrant une procédure de radiation de son action ordinaire pour ne pas avoir respecté l’exigence de prix d’offre de 1,00 USD. La société n’a pas renoué avec la conformité d’ici la date limite du 6 octobre 2025.
Cycurion a déposé une demande d’appel le 20 octobre 2025, ce qui suspend la suspension et le dépôt du Form 25-NSE en attendant la décision d’un panel d’audiences (les audiences ont généralement lieu environ 30–45 jours après la demande). Le conseil a approuvé une réserve d’actions inversée 30:1 le 10 octobre 2025, qui doit entrer en vigueur le 27 octobre 2025. Si la radiation est effective, les actions pourraient passer sur le marché de gré à gré, qui est susceptible d’être moins liquide.
Cycurion (NASDAQ: CYCU) erhielt vom Nasdaq-Personal ein Delisting Determination Letter datiert auf 14. Oktober 2025, der ein Verfahren zur Delistung seiner Stammaktien wegen Nichteinhaltung der $1,00-Offerpreis-Anforderung einleitet. Das Unternehmen hat die Einhaltung bis zur Frist am 6. Oktober 2025 nicht wiederherstellen können.
Cycurion beantragte eine Berufung am 20. Oktober 2025, wodurch die Suspendierung und die Einreichung des Form 25-NSE bis zur Entscheidung eines Hearings Panels ausgesetzt bleiben (Hörungen finden typischerweise etwa 30–45 Tage nach dem Antrag statt). Der Vorstand genehmigte am 10. Oktober 2025 ein 30:1-Reverse-Stock-Split, dessen Inkrafttreten für den 27. Oktober 2025 erwartet wird. Im Falle der Delistung könnten die Aktien auf den Over-the-Counter-Markt wechseln, der voraussichtlich weniger liquide ist.
Cycurion (NASDAQ: CYCU) تلقّت رسالة تحديد إلغاء الإدراج من موظفي ناسداك بتاريخ 14 أكتوبر 2025، مما بدأ إجراءات لإلغاء إدراج أسهمها العادية لأنها لم تستوفِ شرط سعر العرض البالغ 1.00 دولار. ولم تستطع الشركة استعادة الامتثال قبل الموعد النهائي في 6 أكتوبر 2025.
طلبت Cycurion استئنافاً في 20 أكتوبر 2025، وهذا يوقف التعليق وتقديم النموذج 25-NSE حتى قرار لجنة الاستماع (عادةً ما تُعقد الجلسات خلال حوالي 30–45 يوماً من الطلب). ألقت المجلس الموافقة على تجزئة عكسية للأسهم بنسبة 30:1 في 10 أكتوبر 2025، ومن المتوقع أن تسري في 27 أكتوبر 2025. إذا تم الإلغاء، قد تتحول الأسهم إلى سوق خارج البورصة (over-the-counter)، وهو عادةً أقل سيولة.
Cycurion (NASDAQ: CYCU) 收到了来自 Nasdaq 工作人员、日期为 2025年10月14日 的撤销上市决定函，启动将其普通股退市的程序，因为未符合 1.00美元的收盘价要求。公司未在 2025年10月6日 的截止日期前恢复合规。
Cycurion 于 2025年10月20日 提起上诉，请求被保留暂停以及 Form 25-NSE 的提交，直至听证小组作出决定（听证通常在申请后约 30–45 天举行）。董事会于 2025年10月10日 批准了 30:1 的反向分拆，预计于 2025年10月27日 生效。如被退市，股票可能转至场外市场（over-the-counter），这通常流动性较低。
- Appeal filed on October 20, 2025, which stays delisting actions
- Board approved a 30:1 reverse stock split on October 10, 2025
- Reverse split expected effective October 27, 2025
- Reverse split authority previously approved and effective on September 29, 2025
- Nasdaq commenced delisting proceedings on October 14, 2025
- Company failed to regain <$b>1.00 bid price by the October 6, 2025 deadline
- Shares scheduled for delisting at open on October 23, 2025 if no appeal
- Potential move to over-the-counter market could reduce liquidity and depress price
Insights
Nasdaq has moved to delist Cycurion; the company has requested a hearing and is implementing a 30:1 reverse split.
The Staff of Nasdaq determined to commence delisting proceedings after the company failed to regain compliance with the Bid Price Rule following a prior notification; the company filed a request for a Hearings Panel appeal on
Key dependencies and risks include the Panel outcome and whether the reverse split meaningfully restores the closing bid above the
Items to watch: the Panel decision timeline (expect a hearing ~30–45 days after
MCLEAN, Va., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading cybersecurity solutions provider, announced today that it received a Delisting Determination Letter from the staff of Nasdaq Listing Qualifications (the “Staff”) on October 14, 2025, providing that the Staff has determined to commence proceedings to delist the common stock, par value
As previously announced, on April 9, 2025, the Staff notified the Company that, for the prior 30 consecutive business days, the closing bid price of the Company’s common stock had been below the minimum of
The Company has not regained compliance with the Bid Price Rule, and the listed security is now subject to delisting from The Nasdaq Global Market. Unless the Company requests an appeal of the Staff’s determination by October 21, 2025, trading of the Company’s shares of common stock will be scheduled for delisting at the opening of business on October 23, 2025, and Nasdaq intends to file a Form 25-NSE with the SEC, removing the Company’s shares of common stock from listing and registration on The Nasdaq Stock Market.
On October 20, 2025, the Company submitted its request to the Nasdaq Global Market to appeal the Staff’s determination to a Hearings Panel (the “Panel”) pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A hearing request will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Company has been informed by the Staff that Panel hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request.
On October 10, 2025, the Company’s board of directors determined to effect a 30:1 reverse stock split to regain compliance with the Bid Price Rule, which is expected to take effect on October 27, 2025. As previously announced, holders of a majority of the Company’s issued and outstanding common stock, including certain holders of shares of preferred stock, which shares vote together with the shares of common stock, approved a reverse stock split proposal at a reverse stock split ratio ranging between and including 3:1 to 75:1 and in the aggregate not more than 250:1, inclusive, by written consent as set forth in the Company’s definitive Information Statement filed with the U.S. Securities and Exchange Commission on September 9, 2025. The reverse stock split proposal became effective on September 29, 2025.
If the Company does not regain compliance with Nasdaq’s continued listing standards or its appeal is unsuccessful, it is expected that its shares of common stock will be delisted from Nasdaq, in which case, the Company may apply to list its shares of common stock on the over-the-counter market. The over-the-counter market is a significantly more limited market than Nasdaq, and quotation on the over-the-counter market likely results in a less liquid market for existing and potential stockholders of the Company to trade its shares of common stock and could depress the trading price of the shares of common stock. The Company can provide no assurance that its shares of common stock will continue to trade on this market or the over-the-counter market, that broker-dealers will continue to provide public quotes of the shares of common stock, or that the trading volume of the shares of common stock will be sufficient to provide for an efficient trading market.
About Cycurion, Inc.
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future.
More info: www.cycurion.com
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to, the outcomes of the Company’s investigations, any potential legal proceedings, including the John Doe lawsuit, or the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.
Cycurion Investor Relations:
(888) 341-6680
investors@cycurion.com
Cycurion Media Relations:
(888) 341-6680
media@cycurion.com
FAQ
What did Cycurion announce about Nasdaq delisting on October 20, 2025?
When is Cycurion's appeal deadline and what happens if it is missed (CYCU)?
What reverse stock split did Cycurion approve and when will it take effect (CYCU)?
Will filing an appeal stop Nasdaq from delisting Cycurion stock immediately?
What happens to CYCU shares if Nasdaq delists the company?
